DOCSLIB.ORG

Augusta: Beautiful from Amen Corner

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Augusta: Beautiful from Amen Corner The Transition 4th Year Pharmacy Students Entering the Real World of Pharmacy VOLUME V, ISSUE I AUGUST 2017 INSIDE THIS ISSUE: Augusta: Beautiful from Amen Corner Region Spotlight 1 to the Corners of the Savannah I can’t help but smile and laugh staff. It’s hard to imagine a bet- questions and provide guidance when I hear people refer to ter group of mentors and role to students seeking a postgradu- Agent to Watch: 2 “Disgusta”. It’s a misnomer for a models. Whether it’s talking ate residency. This has led to Andexanet Alfa city that most people never about sports with Dr. David greater residency interest and a truly experience. Sure, it Deremer, who will be sorely general feeling of being more doesn’t have the bright lights of missed, asking Dr. Clemmons prepared for the next steps. Atlanta or bustling nightlife of clinical questions, having confi- Amazon Pharmacy: If I could go back and do it all 3 Athens, but it contains the most dence replenished by Dr. Fagan, Prime Shipping again, knowing then what I sacred playing field of sports in or seeking life advice and moti- Your Prescriptions know now, I would rank Augus- the world, shares part of the vation from Drs. Dianne and ta as my top choice ten times strongest river in Georgia, and Rusty May, the open-door poli- out of ten. The people here Calculation Review 3 has one of the largest man-made cy in Augusta has benefited all of have helped shape me as a per- lakes in the country. us at some point or another. son as well as a future pharma- I was born in University Hospi- Take away the shiny new build- cist. So again, all I can do is tal in January of 1993, and Au- ing, the proximity to the hospi- smirk when I hear people refer Lifestyle Corner: 4 gusta has been home ever since. tals, and the networking oppor- to this beautiful city as Stay Fit While You Augusta, to me, is the city that tunities; the Augusta campus “Disgusta.” Sit everyone says they can’t wait to would still be unparalleled be- leave, but no one ever really cause of those who are com- pletely dedicated to their stu- Narcan® to the does. Ask anyone from Augusta, 4 dents in all areas of life. Rescue! and they’ll tell you their family is rooted generations deep in that Aside from the faculty and staff, red Georgia clay. Even more so, the Augusta campus offers a few Augusta features an expansive other unique perks to aid the Rotation Spotlight 5 medical district that rivals any development of future pharma- http://news.uga.edu/releases/article/pharmacy-opens-new- other in the southeast. With six cists. One of these is the ability educational-facility-in-augusta/ hospitals in a twenty-mile radi- to participate in research with us, it’s hard to imagine a better Dr. Segar, Dr. Shenoy, and Dr. place to live for any healthcare Fagan. In fact, full size labs are professional. So what does it being added onto the campus to offer a pharmacy school stu- facilitate student involvement in dent? For me, coming back as a research opportunities. Students student has revolutionized my have been able to make presen- view of the city. tations and contribute publica- https://steamcommunity.com/sharedfiles/filedetails/? Ask any student assigned to tions for novel research in these id=501724370. Accessed August 9, 2017. Augusta what makes the campus labs. Another perk is the vast Written By: Daniel Anderson so special, and I can guarantee network of clinical pharmacists (Augusta, GA) they’ll start with the faculty and who have volunteered their time as mentors to answer P A G E 2 Agent to Watch: Andexanet Alfa Many have heard of Andexanet alfa, yet the agent is not cur- centage of reduced anti-factor Xa activity and the percentage rently FDA-approved. The highly anticipatory nature sur- of effective hemostasis seen in patients who received andex- rounding this agent stems from its potential role of serving as a anet alfa. In regards to safety, an initial bolus and subsequent 2- reversal agent for major bleeds associated with the factor Xa hour infusion of andexanet alfa markedly reduced anti-factor inhibitors class like rivaroxaban or apixaban. Currently, only Xa activity, with effective hemostasis occurring in 79% of pa- two FDA-approved agents exist as reversal agents for antico- tients. However, the study is still awaiting full enrollment to agulants: Idarucizumab (Praxbind®) for dabigatran and Vitamin provide adequate statistical power to support a positive rela- K (phytonadione) for warfarin. The lack of a reversal agent for tionship between andexanet alfa and reduction in anti-factor factor Xa inhibitors is apparent to practitioners right now. Xa activity with clinical hemostatic outcomes. Furthermore, it Therefore, it will become important for pharmacists in all set- was reported that 18 of 67 patients experienced a thrombotic tings to understand the properties of Andexanet alfa if and event or death after being treated with andexanet alfa over a when it becomes FDA- 30-day study period, approved and makes its though the study acknowl- way into the market. edged that a controlled study would be needed to Andexanet alfa is a re- assess whether the fre- combinant modified hu- quency of these events man factor Xa decoy exceeded what is ex- protein. It simply func- pected in patients who tions by acting as a decoy have increased thrombotic for factor Xa without risk.2 having any intrinsic cata- lytic activity.1 By doing In the realm of anticoagu- so, factor Xa inhibitors lation, factor Xa inhibitors bind the decoy protein have their own unique set instead of binding human of advantages: minor drug Portola Pharmaceuticals Andexanet Alfa Mechanism of Action (MOA) Video Sep 12, 2014 https://www.youtube.com/watch? factor Xa. Theoretically, v=LXA7aIAA7yQ and food interactions, a this should decrease plasma lack in the need for lab levels of unbound factor Xa inhibitor and decrease anti-factor monitoring, and convenience of use.1 It will be interesting to Xa activity, which are the main efficacy outcomes being investi- see how the introduction of a reversal agent such as andex- gated in the ANNEXA-4 study currently underway.2 anet alfa will affect the utilization of factor Xa inhibitors. This implication makes the ongoing ANNEXA-4 trial interesting to The ANNEXA-4 study began in 2014 to examine the efficacy pharmacists because it will serve as a resource when faced and safety of andexanet alfa in patients experiencing a poten- with questions about the appropriateness of these effective tially life-threatening acute major bleed associated with factor but dangerous agents. Xa inhibitors. As of 2016, 67 patients have been evaluated and a descriptive preliminary analysis was published in the New Written by: Andrea Tse (Atlanta, GA) England Journal of Medicine (NEJM).2 Reviewed by: Mindi Miller, PharmD BCPS This analysis reported findings on endpoints including the per- Anticogulant Mechanism of Action Reversal Agent Warfarin (Coumadin®) Vitamin K Reductase Inhibitor Vitamin K, Prothrombin Complex Concen- trate (Kcentra®) Enoxaparin (Lovenox®) Vitamin K Reductase Inhibitor No reversal agent currently approved Dabigatran (Pradaxa®) Factor VII and VIII Inhibitor Idarucizumab (Praxbind®) Rivaroxaban (Xarelto®) Factor Xa Inhibitor No reversal agent currently approved Apixaban (Eliquis®) Factor Xa Inhibitor No reversal agent currently approved Edoxaban (Savaysa®) Factor Xa Inhibitor No reversal agent currently approved Betrixaban (Bevyxxa®) Factor Xa Inhibitor No reversal agent currently approved THE TRANSITION P A G E 3 Amazon Pharmacy: Prime Shipping Your Prescriptions As we begin preparing for life after pharmacy school, there are rise in pharmacy schools? More importantly, how will this affect several avenues available. Some of us will match for residencies; the job market that we will be facing in less than a year? Fortu- some will find jobs with retail chains, independents, or hospi- nately, with laws and regulations, Amazon will not be able to tals; and some may even have the oppor- function without pharmacists approving tunity to work for Amazon in the near prescriptions, transferring prescriptions, future. The well-known, fast-growing and navigating electronic prescriptions. electronic commerce (e-commerce) In addition, Amazon has already initiated company has meetings every year to a smaller model of pharmacy involve- discuss its potential role in the pharmacy ment in Japan, where they expanded the industry. This year, the meeting became popular prime delivery service to offer more serious as Amazon hopes to hire a drugs to patients with pharmacists’ ap- general manager to spearhead this new proval. Therefore, pharmacists will be endeavor. integral in the future pharmaceutical With retail, hospital, mail order pharma- component of Amazon’s industry. cies, and delivery services, why would Once a general manager is hired to or- patients turn to Amazon for prescrip- ganize and solve any issues that may tions? Many of us take advantage of Ama- arise, Amazon will be looking at a $25- zon to order school supplies, gifts, books, 50 billion dollar market associated with and more. By entering the pharmacy their involvement in the United States’ market, Amazon hopes to target patients massive pharmaceutical industry. If Ama- who either have high dollar deductible zon is able to offer convenient, cost- plans or who self-pay for their healthcare. https://medium.com/@jajaliao/if-amazon-takes-over-prescription-drugs-whats-left- effective prescriptions for patients and From this perspective, Amazon would for-startups-172a715c6e9c utilize an adequate number pharmacists find its niche in the multibillion-dollar as part of this endeavor, Amazon may be pharmacy industry in providing prescriptions at a lower cost looking at their next successful business scheme, and some of than offered from pharmacy benefit management groups.
Load more

Recommended publications
  • Oral Anticoagulants
    4/26/2018 Disclosure • Kelsey Gander, PharmD, BCACP Direct Oral Anticoagulants: – Declares no financial relationships pertinent to this session When to Use and How to Choose – Declares off-label use of medication will not be discussed during this presentation. Kelsey Gander, PharmD, BCACP Minnesota Academy of Physician Assistants Conference May 11th, 2018 Abbreviations Objectives • DOAC= direct oral anticoagulant 1) Compare and contrast the efficacy and safety • VTE= venous thromboembolism • DVT= deep vein thrombosis of direct oral anticoagulants (DOACs) to • PE= pulmonary embolism warfarin • A-fib, AF= atrial fibrillation 2) Identify which anticoagulant would be most • ESRD= end stage renal disease appropriate for a given patient • ACC= American College of Cardiology • AHA= American Heart Association 3) Recognize when it would not be appropriate • HRS= Heart Rhythm Society to use a DOAC • BID= twice daily Appropriate Abbreviations Patient Case JJ is a 66 y/o male who was hospitalized for pulmonary • NOAC embolism and initiated on anticoagulant therapy one week – Novel Oral Anticoagulant ago. – Chief complaint: – Non-Vitamin K Oral Anticoagulant • Presents to clinic today for INR check, post-hospital discharge follow- up • TSOAC – Past medical history: • Hypertension, hyperlipidemia, osteoarthritis, erectile dysfunction, – Target Specific Oral Anticoagulant BPH, type 2 diabetes, peripheral artery disease – Home medications • DOAC • Acetaminophen 650mg po every 6 hours PRN – Direct Oral Anticoagulant • Diazepam 5mg po at bedtime PRN anxiety
    [Show full text]
  • 76. Which of the Following Is Incorrect Based on the 2018 ASRA Checklist for Managing Local Anesthetic Systemic Toxicity?
    76. Which of the following is incorrect based on the 2018 ASRA Checklist for managing Local Anesthetic Systemic Toxicity? A. The upper limit of lipid emulsion dosing is 12mL/kg B. Monitoring should be at least 4-6 hours after a cardiovascular event or at least 2 hours after a limited CNS event C. 20% lipid emulsion should be used as the initial drug at the first sign of a serious LAST Event D. Epinephrine doses of > 1mcg/kg are recommended 77. Which of the following statements is NOT true with regard to the management of new oral anticoagulants? A. Rivaroxaban (Xarelto) and Apixaban (Eliquis) should be held for at least 72 hours prior to neuraxial block B. Dabigatran (Pradaxa) should be held for 24 to 48 hours prior to neuraxial block in a patient with a compromised GFR C. Dabigatran can be reversed by the monoclonal antibody idarucizumab D. Factor Xa inhibitors, Rivaroxaban and Apixaban, can be effectivelY reversed with andexanet alfa 78. Which answer the correct spread of local anesthetic for an Erector Spinae Plane Block performed at the T5 level? A. Spread between the erector spinae muscle and rhomboid muscle B. Spread lateral to the transverse process, superficial to the erector spinae muscle C. Spread deep to the erector spinae muscle at the transverse process D. Spread deep to the costotransverse ligament, pushing the pleura ventrallY 79. When assessing the lungs with ultrasound, which of the following signs are suggestive a pneumothorax: A. Absence of lung sliding B. Presence of “comet tails” C. Absence of a “lung point” D.
    [Show full text]
  • Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants
    Question Of the Day Archives: Monday, December 5, 2016 Question: Calcium oxalate is a widespread toxin found in many species of plants. What is the needle shaped crystal containing calcium oxalate called and what is the compilation of these structures known as? Answer: The needle shaped plant-based crystals containing calcium oxalate are known as raphides. A compilation of raphides forms the structure known as an idioblast. (Lim CS et al. Atlas of select poisonous plants and mushrooms. 2016 Disease-a-Month 62(3):37-66) Friday, December 2, 2016 Question: Which oral chelating agent has been reported to cause transient increases in plasma ALT activity in some patients as well as rare instances of mucocutaneous skin reactions? Answer: Orally administered dimercaptosuccinic acid (DMSA) has been reported to cause transient increases in ALT activity as well as rare instances of mucocutaneous skin reactions. (Bradberry S et al. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning. 2009 Q J Med 102:721-732) Thursday, December 1, 2016 Question: What is Clioquinol and why was it withdrawn from the market during the 1970s? Answer: According to the cited reference, “Between the 1950s and 1970s Clioquinol was used to treat and prevent intestinal parasitic disease [intestinal amebiasis].” “In the early 1970s Clioquinol was withdrawn from the market as an oral agent due to an association with sub-acute myelo-optic neuropathy (SMON) in Japanese patients. SMON is a syndrome that involves sensory and motor disturbances in the lower limbs as well as visual changes that are due to symmetrical demyelination of the lateral and posterior funiculi of the spinal cord, optic nerve, and peripheral nerves.
    [Show full text]
  • Four-Factor Prothrombin Complex Concentrate Improves Thrombin
    Schenk et al. Thrombosis Journal (2018) 16:1 DOI 10.1186/s12959-017-0158-9 RESEARCH Open Access Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial Bettina Schenk1* , Stephanie Goerke2,3, Ronny Beer4, Raimund Helbok4, Dietmar Fries1 and Mirjam Bachler1,5 Abstract Background: Direct oral anticoagulants (DOACs) pose a great challenge for physicians in life-threatening bleeding events. The aim of this study was to test the efficacy of reversing the DOAC rivaroxaban using four-factor PCC (prothrombin complex concentrate), a non-specific reversing agent. Methods: Patients with life-threatening bleeding events during rivaroxaban treatment were included and administered 25 U kg−1 of PCC. Blood samples were collected immediately prior to as well as after PCC treatment at predefined time intervals. The primary endpoint was defined as the difference in thrombin generation (TG) parameters ETP (endogenous thrombin potential) and Cmax (peak thrombin generation) prior to and ten minutes subsequent to PCC treatment. Results: Thirteen patients, of whom the majority suffered from intra-cranial haemorrhage (ICH) or subdural haemorrhage (SDH), were included and administered PCC. The results show that the ETP (TG) significantly (p = 0.001) improved by 68% and Cmax (TG) by 54% (p = 0.001) during PCC treatment. In addition, the Quick value (prothrombin time: QuickPT) significantly improved by 28% and the activated partial thromboplastin time (aPTT) was PT decreased by 7% ten minutes after PCC administration. Cmax was reduced at baseline, but not ETP, aPTT or Quick . Lag time until initiation (TG, tlag), thromboelastometry clotting time (CTEXTEM) and time to peak (TG, tmax) correlated best with measured rivaroxaban levels and were out of normal ranges at baseline, but did not improve after PCC administration.
    [Show full text]
  • Pharmacotherapy Pearls for Emergency Neurological Life Support Theresa Human1*, Eljim Tesoro2* and Sarah Peacock3
    Neurocrit Care https://doi.org/10.1007/s12028-019-00830-4 PHARMACOTHERAPY Pharmacotherapy Pearls for Emergency Neurological Life Support Theresa Human1*, Eljim Tesoro2* and Sarah Peacock3 © 2019 Neurocritical Care Society Abstract The appropriate use of medications during Emergency Neurological Life Support (ENLS) is essential to optimize patient care. Important considerations when choosing the appropriate agent include the patient’s organ function, medication allergies, potential adverse drug efects, drug interactions, critical illness, and age-related pathophysi- ologic changes. Medications used during ENLS include hyperosmolar therapy, antiseizures, antithrombotics, antico- agulant reversal hemostatic agents, antishivering agents, neuromuscular blockers, antihypertensive agents, sedatives, vasopressors inotropes, and antimicrobials. This chapter focuses on key pharmacokinetic and pharmacodynamic characteristics, advantages and disadvantages, and clinical pearls of these therapies, thereby providing practitioners with essential drug information to optimize pharmacotherapy in acutely ill neurocritical care patients. Keywords: ENLS, Pharmacotherapy, Medication, Adverse drug event, Drug interaction Introduction provider optimize medication management in the acute Neurocritical care patient management is highly com- period of neurologic injury. plicated, especially when trying to optimize therapy dur- ing the acute injury. Pharmacologic management must Chapter Outline be carefully considered in order to minimize cognitive • Hyperosmolar
    [Show full text]
  • In-Vitro Sorbent-Mediated Removal of Edoxaban from Human Plasma and Albumin Solution
    University of Massachusetts Medical School eScholarship@UMMS Open Access Articles Open Access Publications by UMMS Authors 2020-09-01 In-Vitro Sorbent-Mediated Removal of Edoxaban from Human Plasma and Albumin Solution Alexandra A. Angheloiu Temple University Et al. Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/oapubs Part of the Fluids and Secretions Commons, Hemic and Immune Systems Commons, Investigative Techniques Commons, Laboratory and Basic Science Research Commons, and the Pharmaceutical Preparations Commons Repository Citation Angheloiu AA, Tan Y, Ruse C, Shaffer SA, Angheloiu GO. (2020). In-Vitro Sorbent-Mediated Removal of Edoxaban from Human Plasma and Albumin Solution. Open Access Articles. https://doi.org/10.1007/ s40268-020-00308-1. Retrieved from https://escholarship.umassmed.edu/oapubs/4354 Creative Commons License This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. Drugs in R&D (2020) 20:217–223 https://doi.org/10.1007/s40268-020-00308-1 ORIGINAL RESEARCH ARTICLE In‑Vitro Sorbent‑Mediated Removal of Edoxaban from Human Plasma and Albumin Solution Alexandra A. Angheloiu1 · Yanglan Tan2,3 · Cristian Ruse4 · Scott A. Shafer2,3 · George O. Angheloiu5 Published online: 15 May 2020 © The Author(s) 2020 Abstract Background and Objective Based on previous experience of sorbent-mediated ticagrelor, dabigatran, and radiocontrast agent removal, we set out in this study to test the efect of two sorbents on the removal of edoxaban, a factor Xa antagonist direct oral anticoagulant.
    [Show full text]
  • PRAC Draft Agenda of Meeting 11-14 May 2020
    11 May 2020 EMA/PRAC/257460/2020 Human Division Pharmacovigilance Risk Assessment Committee (PRAC) Draft agenda for the meeting on 11-14 May 2020 Chair: Sabine Straus – Vice-Chair: Martin Huber 11 May 2020, 10:30 – 19:30, via teleconference 12 May 2020, 08:30 – 19:30, via teleconference 13 May 2020, 08:30 – 19:30, via teleconference 14 May 2020, 08:30 – 16:00, via teleconference Organisational, regulatory and methodological matters (ORGAM) 28 May 2020, 09:00-12:00, via teleconference Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised. Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006, Rev. 1). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020.
    [Show full text]
  • Drug Consumption in Current Year (Period 201901
    Page 1 Drug consumption in current year (Period 202001 - 202012) Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change % A ALIMENTARY TRACT AND METABOLISM 323,80 3 4 321 589 7 4 A01 STOMATOLOGICAL PREPARATIONS 14,28 4 12 2 090 9 8 A01A STOMATOLOGICAL PREPARATIONS 14,28 4 12 2 090 9 8 A01AA Caries prophylactic agents 11,90 3 14 663 8 9 A01AA01 sodium fluoride 11,90 3 14 610 8 10 A01AA03 olaflur - - - 53 1 -2 A01AB Antiinfectives for local oral treatment 2,36 8 2 1 266 10 15 A01AB03 chlorhexidine 2,02 6 -3 930 6 5 A01AB11 various 0,33 21 57 335 21 55 A01AB22 doxycycline - - - 0 - -100 A01AC Corticosteroids for local oral treatment - - - 113 1 -26 A01AC01 triamcinolone - - - 113 1 -26 A01AD Other agents for local oral treatment 0,02 0 -28 49 0 -32 A01AD02 benzydamine 0,02 0 -28 49 0 -32 A02 DRUGS FOR ACID RELATED DISORDERS 73,05 3 3 30 885 4 -5 A02A ANTACIDS 2,23 1 1 3 681 1 3 A02AA Magnesium compounds 0,07 22 -7 141 22 -7 A02AA04 magnesium hydroxide 0,07 22 -7 141 22 -7 A02AD Combinations and complexes of aluminium, 2,17 0 1 3 539 0 4 calcium and magnesium compounds A02AD01 ordinary salt combinations 2,17 0 1 3 539 0 4 A02B DRUGS FOR PEPTIC ULCER AND 70,82 3 3 27 205 5 -7 GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 0,17 7 -77 551 10 -29 A02BA02 ranitidine 0,00 1 -100 1 1 -100 A02BA03 famotidine 0,16 7 48 550 10 43 A02BB Prostaglandins 0,04 62 55 80 62 55 A02BB01 misoprostol 0,04 62 55 80 62 55 A02BC Proton pump inhibitors 69,26 3 4 23 531 4 -8
    [Show full text]
  • Reversal Agents
    R E V E R S A L A G E N T S Opioids Nalaxone (Narcan) Opioid effects may outlast the reversal's duration of action Continue monitoring 3-4 hrs Benzodiazepines Flumazenil (Romazicon) May lower seizure threshold May cause confusion, agitation, hypertension, and alterations in heart rate Beta Blockers Glucagon Monitor for hyperglycemia May cause hypokalemia Heparin Protamine Sulfate May cause hypotension Risk for anaphylaxis Has weak anticoagulant effect Risk for thrombotic event Warfarin PCC - Vitamin K - FFP Treatment based on severity of bleeding An exhibitImiomne tdoiauter - oPnCC R aandp Vhita Kel Joo's mostF aisct o- FnFiPc works! Within 6 hrs - Vitamin K Risk for thrombotic event Factor Xa Inhibitors Andexanet alfa Risk for thrombotic event May cause cardiogenic shock, heart failure exacerbations, UTI, acute respiratory failure, and pneumonia © Digital Health Media LLC R E F E R E N C E S APSF. (2018, August 5). New Factor Xa Inhibitor (Xarelto®) (Eliquis®) Reversal Agent. Retrieved from Anesthesia Patient Safety Foundation website: https://www.apsf.org/news- updates/new-factor-xa-inhibitor-xarelto-eliquis-reversal-agent/ CHEMM. (n.d.). Naloxone. Retrieved from https://chemm.nlm.nih.gov/countermeasure _naloxone.htm#adminHanley, Deglin, J. H., & Vallerand, A. H. (2007). Davis’s drug guide for nurses (11th ed.). Philadelphia, PA: F. A. Davis Company J. P. (2004). Warfarin reversal. Journal of Clinical Pathology, 57(11), 1132–1139 https://doi.org /10.1136/jcp.2003.008904 Kang, M., & Ghassemzadeh, S. (2019). Benzodiazepine Toxicity. In StatPearls. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK482238/ Ni Ainle, F., Preston, R.
    [Show full text]
  • Drug Consumption at Wholesale Prices in 2017 - 2020
    Page 1 Drug consumption at wholesale prices in 2017 - 2020 2020 2019 2018 2017 Wholesale Hospit. Wholesale Hospit. Wholesale Hospit. Wholesale Hospit. ATC code Subgroup or chemical substance price/1000 € % price/1000 € % price/1000 € % price/1000 € % A ALIMENTARY TRACT AND METABOLISM 321 590 7 309 580 7 300 278 7 295 060 8 A01 STOMATOLOGICAL PREPARATIONS 2 090 9 1 937 7 1 910 7 2 128 8 A01A STOMATOLOGICAL PREPARATIONS 2 090 9 1 937 7 1 910 7 2 128 8 A01AA Caries prophylactic agents 663 8 611 11 619 12 1 042 11 A01AA01 sodium fluoride 610 8 557 12 498 15 787 14 A01AA03 olaflur 53 1 54 1 50 1 48 1 A01AA51 sodium fluoride, combinations - - - - 71 1 206 1 A01AB Antiinfectives for local oral treatment 1 266 10 1 101 6 1 052 6 944 6 A01AB03 chlorhexidine 930 6 885 7 825 7 706 7 A01AB11 various 335 21 216 0 227 0 238 0 A01AB22 doxycycline - - 0 100 0 100 - - A01AC Corticosteroids for local oral treatment 113 1 153 1 135 1 143 1 A01AC01 triamcinolone 113 1 153 1 135 1 143 1 A01AD Other agents for local oral treatment 49 0 72 0 104 0 - - A01AD02 benzydamine 49 0 72 0 104 0 - - A02 DRUGS FOR ACID RELATED DISORDERS 30 885 4 32 677 4 35 102 5 37 644 7 A02A ANTACIDS 3 681 1 3 565 1 3 357 1 3 385 1 A02AA Magnesium compounds 141 22 151 22 172 22 155 19 A02AA04 magnesium hydroxide 141 22 151 22 172 22 155 19 A02AD Combinations and complexes of aluminium, 3 539 0 3 414 0 3 185 0 3 231 0 calcium and magnesium compounds A02AD01 ordinary salt combinations 3 539 0 3 414 0 3 185 0 3 231 0 A02B DRUGS FOR PEPTIC ULCER AND 27 205 5 29 112 4 31 746 5 34 258 8
    [Show full text]
  • The Clinical Insight
    The Clinical InSight March 2018 800.361.4542 | envisionrx.com Recent FDA Approvals New Medications Trade Name Dosage Form Manufacturer Indication(s) Approval Date (generic name) Strength For use in combination with other antiretroviral(s) for the treatment of human immunodeficiency virus type 1 Trogarzo TaiMed Biologics Injection, (HIV-1) infection in heavily March 3, 2018 (ibalizumab-uiyk) USA 150 mg/mL treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen. For the treatment of adults Ilumya with moderate-to-severe Merck Sharp & Injection, (tildrakizumab- plaque psoriasis who are March 20, 2018 Dohme 100 mg/mL asmn) candidates for systemic therapy or phototherapy. New Combinations and Formulations Trade Name Dosage Form Manufacturer Indication(s) Approval Date (generic name) Strength For use as a complete Symfi regimen for the treatment of (efavirenz; Tablet, human immunodeficiency lamivudine; Mylan Specialty 600 mg; 300 mg; virus type 1 (HIV-1) infection March 22, 2018 tenofovir L.P. 300 mg in adult and pediatric disoproxil patients weighing at least 40 fumarate) kg. New Generics Generic Name Trade Name Dosage Form Manufacturer(s) Approval Date Cinacalcet Cipla Ltd.; Aurobindo Sensipar Tablets March 8, 2018 Hydrochloride Pharma Limited Confidential - Document has confidential information and may not be copied, published or distributed, in whole or in part, in any 800.361.4542 | envisionrx.com 2 form or medium, without EnvisionRxOptions’ prior written consent. Pipeline New
    [Show full text]
  • Review Article an Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants
    Hindawi Advances in Hematology Volume 2020, Article ID 7636104, 10 pages https://doi.org/10.1155/2020/7636104 Review Article An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants Mark Terence P. Mujer,1 Manoj P. Rai ,1 Varunsiri Atti,1 Ian Limuel Dimaandal,2 Abigail S. Chan ,3 Shiva Shrotriya,1 Krishna Gundabolu,4,5 and Prajwal Dhakal4,5 1Department of Medicine, Michigan State University, East Lansing, MI, USA 2Department of Internal Medicine, University of Connecticut, Farmington, CT, USA 3Department of Internal Medicine, Sinai Hospital of Baltimore, Baltimore, MD, USA 4Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA 5Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA Correspondence should be addressed to Manoj P. Rai; [email protected] Received 8 May 2019; Revised 26 August 2019; Accepted 25 September 2019; Published 27 January 2020 Academic Editor: Erwin Strasser Copyright © 2020 Mark Terence P. Mujer et al. +is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Non-vitamin K antagonist oral anticoagulants (NOACs) include thrombin inhibitor dabigatran and coagulation factor Xa inhibitors rivaroxaban, apixaban, edoxaban, and betrixaban. NOACs have several benefits over warfarin, including faster time to the achieve effect, rapid onset of action, fewer documented food and drug interactions, lack of need for routine INR monitoring, and improved patient satisfaction. Local hemostatic measures, supportive care, and withholding the next NOAC dose are usually sufficient to achieve hemostasis among patients presenting with minor bleeding.
    [Show full text]